Oxford Asset Management’s Cabaletta Bio CABA Stock Holding History

Oxford Asset Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,405	Closed	-$21.3K	–	552
2025 Q1	$21.3K	Buy	+15,405	New	+$32.8K	0.01%	464

Other funds holding CABA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Oxford Asset Management's CABA Position: Q2 2025 in Review

Oxford Asset Management sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 15,405 shares — an estimated $21.3K sold.

Oxford Asset Management first reported a position in CABA in Q1 2025 and held it in 1 quarter. The position peaked at $21.3K in Q1 2025. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

Oxford Asset Management reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
Oxford Asset Management sold 15,405 Cabaletta Bio shares in Q2 2025, an estimated $21.3K.
Oxford Asset Management first reported a position in Cabaletta Bio in Q1 2025 and held it in 1 quarter.
Oxford Asset Management's Cabaletta Bio position peaked at $21.3K in Q1 2025.
86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on Oxford Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.